Surrozen, Inc./DE Logo

Surrozen, Inc./DE

Develops regenerative antibodies modulating the Wnt pathway to repair tissues and restore organs.

SRZN | US

Overview

Corporate Details

ISIN(s):
KYG2445M1033 (+2 more)
LEI:
Country:
United States of America
Address:
171 OYSTER POINT BLVD, 94080 SOUTH SAN FRANCISCO
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Surrozen, Inc. is a clinical-stage biotechnology company that discovers and develops drug candidates to repair tissues and restore organs damaged by serious diseases. The company is pioneering a new class of targeted regenerative antibodies designed to selectively modulate the Wnt pathway, a key biological mechanism for the body's natural repair and self-renewal processes. Surrozen's platform develops tissue-specific antibodies with a current focus on therapeutic areas such as ophthalmology. The company's mission is to unlock the body's regenerative power to transform the treatment of a broad range of injuries and diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Surrozen, Inc./DE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Surrozen, Inc./DE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Surrozen, Inc./DE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea
039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France
OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan
4766
Passage BIO, Inc. Logo
Developing genetic medicines for severe CNS and neurodegenerative disorders.
United States of America
PASG
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway
PCIB
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye
PCILT
PDS Biotechnology Corp Logo
Developing T-cell activating immunotherapies for cancer and infectious diseases.
United States of America
PDSB
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan
7066
PepGen Inc. Logo
Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.
United States of America
PEPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.